EUCLID
Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease
Doente / População Intervenção / Exposição Comparação Desfecho
In 13,885 patients with symptomatic peripheral artery disease, ticagrelor monotherapy did not reduce cardiovascular death, myocardial infarction or ischaemic stroke compared with clopidogrel monotherapy.
N
13 885
Desenho
Double-blind, event-driven RCT
Desfecho
Composite of CV death, MI or ischaemic stroke
Relevância
2
Resultado10.8 % vs 10.6 % over a median 30 months (HR 1.02; 95 % CI 0.92–1.13; p=0.65). Acute limb ischaemia and major bleeding 1.7 % and 1.6 % in both arms.
Hiatt WR, Fowkes FG, et al. N Engl J Med. 2017;376(1):32-40. 10.1056/NEJMoa1611688
Discussão e crítica
A clean, fully powered null result with no aspirin arm, so it cannot address antiplatelet choice beyond the two drugs tested. Its value is negative evidence: escalating single-antiplatelet potency buys nothing in PAD, and clopidogrel remains the reference monotherapy.